Body Location or Region
HLTH24: Atropos Health Introduces AI-Powered Chat Co-Pilot for Rapid Real-World Evidence Generation
Atropos Health, HLTH24, Chat-Based AI Co-Pilot, Real-World Evidence, Generative AI, Healthcare Evidence Generation, GENEVA OS, ChatRWD
IO Biotech’s IO102-IO103 Vaccine in Combination with Keytruda Shows Promising Results in Phase 2 Trial for Advanced Squamous Cell Carcinoma of the Head and Neck
IO Biotech, IO102-IO103, Keytruda (pembrolizumab), Phase 2 trial, Squamous cell carcinoma of the head and neck (SCCHN), Cancer vaccine, Immunotherapy
OS Therapies Refiles IPO for $6M to Fund Phase 2 HER2 Drug and Preclinical ADCs
OS Therapies, IPO, HER2 drug, preclinical ADCs, immunotherapy, NYSE American exchange
BioMarin’s Brineura Receives Significant Label Expansion from FDA for Children Under 3 with CLN2 Disease
BioMarin, Brineura, FDA, Label Expansion, CLN2 Disease, Children Under 3, Cerliponase Alfa, Intraventricular Injection, Motor Ability Deterioration, Neurodegenerative Symptoms
Projected $270 Billion Orphan Drug Market by 2028: A Comprehensive Analysis of Leading Players J&J, Vertex, and Roche
Orphan drugs, rare diseases, J&J, Vertex, Roche, market growth, 2028, Evaluate
From Alpine’s Elite Data Room to Vertex’s VIP: A Shift in Biotech Dominance
Alpine, Vertex, biotech, data room, exclusivity, VIP, shift, dominance.
Vertex’s Acquisition of Alpine Immune Sciences for Povetacicept: Humira-like Potential in IgAN, but Indication Variations Matter
Vertex, Alpine Immune Sciences, Povetacicept (ALPN-303), IgA nephropathy (IgAN), Humira-like potential, Multiple autoimmune diseases
Vertex Initiates FDA Rolling Review for Non-Opioid Pain Medication Suzetrigine (VX-548)
Vertex Pharmaceuticals, Suzetrigine (VX-548), Non-opioid painkiller, FDA rolling review, Acute pain
Vertex Acquires Alpine Immune Sciences for $4.9 Billion to Boost Immunology Trail
Vertex Pharmaceuticals, Alpine Immune Sciences, $4.9 billion acquisition, Immunology trail
Boundless Bio, Oncology Startup Targeting Extrachromosomal DNA, Files for $100 Million IPO
Boundless Bio, Oncology Startup, Initial Public Offering (IPO), Extrachromosomal DNA (ecDNA), Small Molecule Drugs (ecDTx), Checkpoint Kinase 1 Inhibitors, Phase 1 Trials, Nasdaq Listing (Symbol: BOLD), Backed by Bayer and Arch Venture Partners, Preliminary Data Expected in Second Half of 2024